Glenmark Issues Recall On 114 Batches Due To Life-Threatening Risk

Glenmark Pharmaceuticals announced a recall of 114 batches of 750mg potassium chloride extended-release capsules due to issues with their dissolution. This recall stems from concerns that incomplete dissolution could lead to elevated potassium levels, known as hyperkalemia, which can trigger irregular heartbeats and potentially cardiac arrest.

These capsules are typically prescribed to treat low potassium levels (hypokalemia) in patients, especially those with conditions like hypertension, heart failure, or kidney dysfunction. Glenmark emphasized the risk of developing hyperkalemia among users, highlighting potential severe adverse effects, including life-threatening complications.

The affected batches were distributed nationwide in the U.S., with expiry dates ranging from June 2024 to September 2025. This recall follows Glenmark's recent efforts to manage financial challenges, including a significant debt reduction strategy announced last year involving the sale of a major portion of its pharmaceutical ingredient business.